Israel Active

Israel’s Zebra Medical Vision (reported previously) is to trial its technology at the National Health Service in Glasgow and Assuta Medical Centers in Israel. It will be used to detect people at risk of developing osteoporosis.

For the first time in Israel, surgeons at Israel’s Sourasky (Ichilov) medical center implanted a Medtronic Percept DBS pacemaker in an epileptic patient. It records brain activity in addition to performing electrical stimulation. Medtronic owns several Israeli companies and has an Israeli R&D center.

Israel’s GGTUDE (mentioned previously) has 7 free apps in its digital mental-health platform. It has now added GG Self Care, which provides a research-backed, personalized digital intervention for Covid-19-related psychological difficulties. Just 3 minutes a day.

Tel Aviv University researchers have discovered that the hair cells in the inner ear, vital for hearing, develop before birth in the same way that crystals form. They proved this using new 3D time-lapse imaging technology and computational simulations of the development of atoms in the hair cells.

Israel’s Binah.ai (reported previously) is partnering Europe’s largest insurance group, Generali Deutschland. The German company will integrate Binah's health status vital signs monitoring technology in its new mobile application named VitalSigns&Care.

In the first trial on humans, Israeli scientists have shown hyperbaric oxygen therapy (HBOT) can reduce two key biological hallmarks of aging - telomere length shortening and accumulation of senescent cells. These factors lower the risk of cancer, dementia, Alzheimer’s and much more.

Scientists at Tel Aviv University have used CRISPR gene editing in the lab to treat some of the most aggressive of cancers. They improved Glioblastoma (brain cancer) survival rates by 30%, but for metastatic (secondary) ovarian cancer, survival was increased by a huge 80%.

Israel’s Oncohost (reported previously) presented the results of its latest proteomic (proteins) cancer study to the Society for Immunotherapy of Cancer’s (SITC). Oncohost’s PROphet host response profiling platform can predict the best therapy to use for specific cancer patients.

Two Israeli companies OutSense and Olive Diagnostics have developed innovative devices that remove the embarrassing and potentially unhygienic procedure of collecting urine and fecal samples for disease diagnosis. Their real-time passive diagnostic sensors can be fixed to any toilet.

Israel’s K Health (reported previously) has partnered with the Mayo Clinic to improve and accelerate deployment of K Health’s virtual therapy models. K Health enables people to receive comprehensive medical insights and immediate treatment in their homes.